StockNow
Log in
U.S. Markets

Boston Scientific (BSX) Q2 2026 (USD): EPS 0.86 (exp. 0.83), Revenue 5.44bln (exp. 5.37bln); FY adj. EPS view 3.28-3.32 (exp. 3.36)

StockNow breaking-news AI analysis

BSX beat Q2 earnings and revenue expectations but issued conservative FY guidance below consensus, overshadowed by a major $800M restructuring plan aimed at long-term cost efficiency amidst rising competition.

News detail

Q3 adj. EPS view 0.80-0.82 (exp. 0.84).

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement

Geopolitics

The draft agreed to by Iranian and Omani negotiators awaits final approval from Iran’s supreme leader, two regional officials told The Associated Press on Wednesday

U.S. Economy

US ADP Employment Change (Jul) 44K vs. Exp. 70K (Prev. 98K)